Clarity Pharmaceuticals treats the first patient in a clinical study for therapeutic prostate cancer.

Clarity Pharmaceuticals (CU6) has dosed its first patient in its therapeutic prostate cancer trial.

The research is part of Clarity's SECuRE clinical trial, which is investigating targeted copper theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer.

The trial will be a single-arm dose-escalation study including up to 44 participants in the United States.

The trial's goal is to assess the safety and effectiveness of 67Cu-SAR-bisPSMA as a treatment.

The trial's Safety Review Committee recommended that the trial proceed into therapeutic applications after reviewing the first patient's results.

Clarity stated that its preclinical and clinical findings to date encouraged its exploration of the optimised SAR-bisPSMA product in other cancer applications, particularly where the theranostic approach may be useful.

Clarity Executive Chairman Alan Taylor stated, "We are very eager to move on with our second theranostic study and to continue researching the advantages of TCTs."

"Prostate cancer is one of the most common oncology indications, and there is a considerabale unmet need for improved patient diagnosis and treatment."

if you like the information given by us then click on the button below